无码欧美成人av天堂456软件,大胆日本熟妇XXXX,9277在线观看免费播放,4p三个男人让我爽了一夜

抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：

1. 磷酸化血小板源性生長(zhǎng)因子受體α費(fèi)用 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件；

3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴(lài)氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價(jià)結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對(duì)生物素化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用；

8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。

產(chǎn)品訂購(gòu)信息：
英文名稱(chēng)  Anti-Phospho-PDGFRA(Tyr762) 

中文名稱(chēng)   磷酸化血小板源性生長(zhǎng)因子受體α費(fèi)用 

別    名  PDGFRA(phospho Y762); PDGF Receptor alpha(Tyr849)/PDGF Receptor beta (Tyr857); Platelet–dirived growth factor receptor-alpha; Alpha platelet derived growth factor receptor; CD 140a; CD140a; CD140a antigen; MGC74795; PDGF alpha chain; PDGF R alpha; PDGFR 2; PDGFR A; PDGFR alpha; PDGFR2; PDGFRA; Platelet derived growth factor receptor 2; Platelet derived growth factor receptor alpha; Platelet derived growth factor receptor alpha polypeptide; PGFRA_HUMAN.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來(lái)源   Rabbit

克隆類(lèi)型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Dog 

產(chǎn)品類(lèi)型   一抗 磷酸化抗體  

研究領(lǐng)域     免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 轉(zhuǎn)錄調(diào)節(jié)因子 激酶和磷酸酶 細(xì)胞膜受體

蛋白分子量  predicted molecular weight: 117kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human PDGFRA around the phosphorylation site of Tyr762 [SL(p-Y)DR] 

亞    型   IgG

純化方法   affinity purified by Protein A

儲(chǔ) 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化血小板源性生長(zhǎng)因子受體α費(fèi)用 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 The PDGF Receptor Type A (Alpha platelet-derived growth factor receptor precursor, CD140a antigen), a 170kD protein, binds all three isoforms of PDGF with high affinity whereas the PDGF Receptor Type B, a 190kD protein, appears to bind only the PDGF BB homodimer with high affinity. Both receptors are transmembranous, ligand activated protein tyrosine kinases, which phosphorylate a number of important signal transduction proteins, which are bound with differential affinities via SH2 domains. The response of any given cell to PDGF will depend on the types of receptors displayed on the surface and isoforms of PDGF present in the extracellular environment.

Function : Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for normal skeleton development and cephalic closure during embryonic development. Required for normal development of the mucosa lining the gastrointestinal tract, and for recruitment of mesenchymal cells and normal development of intestinal villi. Plays a role in cell migration and chemotaxis in wound healing. Plays a role in platelet activation, secretion of agonists from platelet granules, and in thrombin-induced platelet aggregation. Binding of its cognate ligands - homodimeric PDGFA, homodimeric PDGFB, heterodimers formed by PDGFA and PDGFB or homodimeric PDGFC -leads to the activation of several signaling cascades; the response depends on the nature of the bound ligand and is modulated by the formation of heterodimers between PDGFRA and PDGFRB. Phosphorylates PIK3R1, PLCG1, and PTPN11. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate, mobilization of cytosolic Ca(2+) and the activation of protein kinase C. Phosphorylates PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, and thereby mediates activation of the AKT1 signaling pathway. Mediates activation of HRAS and of the MAP kinases MAPK1/ERK2 and/or MAPK3/ERK1. Promotes activation of STAT family members STAT1, STAT3 and STAT5A and/or STAT5B. Receptor signaling is down-regulated by protein phosphatases that dephosphorylate the receptor and its down-stream effectors, and by rapid internalization of the activated receptor.

Subunit : Interacts with homodimeric PDGFA, PDGFB and PDGFC, and with heterodimers formed by PDGFA and PDGFB. Monomer in the absence of bound ligand. Interaction with dimeric PDGFA, PDGFB and/or PDGFC leads to receptor dimerization, where both PDGFRA homodimers and heterodimers with PDGFRB are observed. Interacts (tyrosine phosphorylated) with SHB (via SH2 domain). Interacts (tyrosine phosphorylated) with SHF (via SH2 domain). Interacts (tyrosine phosphorylated) with SRC (via SH2 domain). Interacts (tyrosine phosphorylated) with PIK3R1. Interacts (tyrosine phosphorylated) with PLCG1 (via SH2 domain). Interacts (tyrosine phosphorylated) with CRK, GRB2 and GRB7. Interacts with human cytomegalovirus/HHV-5 envelop glycoprotein B/gB.

Subcellular Location : Cell membrane; Single-pass type I membrane protein. Note=The activated receptor is rapidly internalized and degraded.

Post-translational modifications : N-glycosylated.

Ubiquitinated, leading to its degradation (Probable).

Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-731 and Tyr-742 is important for interaction with PIK3R1. Phosphorylation at Tyr-720 and Tyr-754 is important for interaction with PTPN11. Phosphorylation at Tyr-762 is important for interaction with CRK. Phosphorylation at Tyr-572 and Tyr-574 is important for interaction with SRC and SRC family members. Phosphorylation at Tyr-988 and Tyr-1018 is important for interaction with PLCG1.

DISEASE : Note=A chromosomal aberration involving PDGFRA is found in some cases of hypereosinophilic syndrome. Interstitial chromosomal deletion del(4)(q12q12) causes the fusion of FIP1L1 and PDGFRA (FIP1L1-PDGFRA). Mutations that cause overexpression and/or constitutive activation of PDGFRA may be a cause of hypereosinophilic syndrome.

Defects in PDGFRA are a cause of gastrointestinal stromal tumor (GIST) [MIM:606764]. Note=Mutations that cause constitutive activation of PDGFRA may be a cause of gastrointestinal stromal tumor (GIST).

Similarity : Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Contains 5 Ig-like C2-type (immunoglobulin-like) domains.

Contains 1 protein kinase domain.

Database links : UniProtKB/Swiss-Prot: P16234.1

PDGFR-α是膜受體，具有酪氨酸酶的活性，與其配體PDGF結(jié)合后激活與細(xì)胞增殖有關(guān)的酶及基因。 PDGFR亦表達(dá)于上皮、內(nèi)皮細(xì)胞，、皮膚、腎小球等上皮細(xì)胞均有PDGFR表達(dá). 亦有學(xué)者報(bào)道血小板源性生長(zhǎng)因子受體α抗體在細(xì)胞胞漿胞膜、胞核都有不同的表達(dá)還有人認(rèn)為：PDGF及其受體一般表達(dá)于浸潤(rùn)組織的細(xì)胞附近，組織缺血損傷、腎小球高壓、免疫因素作用、細(xì)胞浸潤(rùn)、實(shí)質(zhì)細(xì)胞活化等導(dǎo)致PDGFR表達(dá)增強(qiáng)。

抗體的鑒定：

1）磷酸化血小板源性生長(zhǎng)因子受體α費(fèi)用 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來(lái)鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來(lái)表示。交叉反應(yīng)率可用競(jìng)爭(zhēng)抑制試驗(yàn)測(cè)定。以不同濃度抗原和近似抗原分別做競(jìng)爭(zhēng)抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無(wú)窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫(kù)侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測(cè)定對(duì)抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。

Human P27 protein ELISA Kit 人P27蛋白Multi-class antibodies規(guī)格： 48T

Anti-HCG Alpha 人絨毛膜激素α亞基抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh MIP4/CCL18 巨噬細(xì)胞蛋白18抗體 規(guī)格 0.1ml

MLCK(Human myosin light chain kinase) ELISA Kit 人肌球蛋白輕鏈激酶 96T

RBM20 英文名稱(chēng)： RNA結(jié)合蛋白20抗體 0.1ml

CHADL 英文名稱(chēng)： 軟骨蛋白樣蛋白抗體 0.1ml

Anti-HCG Alpha 人絨毛膜激素α亞基抗體Multi-class antibodies規(guī)格： 0.1ml

C5a(Mouse Complement fragment 5a)ELISA Kit 小鼠補(bǔ)體片斷5aMulti-class antibodies規(guī)格： 48T

Anti-CNR-2/FITC 熒光素標(biāo)記鈣粘蛋白相關(guān)的神經(jīng)受體2抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh DHPS 脫氧輔合酶蛋白抗體 規(guī)格 0.2ml

Insulin Protein/Cy3 熒光素Cy3標(biāo)記豬蛋白 0.1ml

LAMR1(CT) 英文名稱(chēng)： 層粘連蛋白受體1抗體(C端) 0.2ml

磺胺嘧啶檢測(cè)試劑盒 96孔/盒 動(dòng)物組織/水產(chǎn)/蜂蜜

Anti-CNR-2/FITC 熒光素標(biāo)記鈣粘蛋白相關(guān)的神經(jīng)受體2抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-Integrin avb3/FITC 熒光素標(biāo)記整合素avb3抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-S6PDH/FITC 熒光素標(biāo)記抗6-磷酸山梨醇脫氫酶抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh ANKRD20A3 錨蛋白重復(fù)結(jié)構(gòu)域蛋白20A3抗體 規(guī)格 0.2ml

Rabbit Anti-Monkey IgM/Bio 生物素標(biāo)記的兔抗猴IgM 0.3ml

Glypican 6 英文名稱(chēng)： 磷脂?；嫉鞍拙厶?6抗體 0.2ml

Rhesus antibody Rh Rabbit Anti-human IgG F(ab')2/APC APC標(biāo)記的兔抗人IgG F(ab')2 規(guī)格 0.1ml

Anti-S6PDH/FITC 熒光素標(biāo)記抗6-磷酸山梨醇脫氫酶抗體IgGMulti-class antibodies規(guī)格： 0.2ml

大鼠磷酸化乙酰輔酶A羧化酶(pACCase)ELISA試劑盒 96T/48T 試劑盒 組裝/原裝

人神經(jīng)元凋亡抑制蛋白(NAIP)免疫試劑盒 Human NAIP ELISA Kit

MouseGrowthHormoneReleasingPeptide,GHRPELISAKit小鼠生長(zhǎng)激素釋放多肽(GHRP)ELISA試劑盒規(guī)格：96T/48T

蛋白表達(dá)西方雜交分析試劑盒-LEPTIN5次

HumanmeaslesvirusIgM,MVIgMELISA試劑盒人病毒IgM(MVIgM)ELISA試劑盒規(guī)格：96T/48T

HumanPlacealalkalinepkosphatase,PLAPELISAKit人胎盤(pán)堿性磷酸酶(PLAP)ELISA試劑盒規(guī)格：96T/48T

大鼠基轉(zhuǎn)移酶(ALT)ELISA試劑盒 ，英文名： ALT ELISA Kit

Mouse alpha glathione S ansferase (-GST) ELISA Kit 小鼠α谷胱甘肽S轉(zhuǎn)移酶(α-GST)ELISA試劑盒

ELISA 小鼠促卵泡素(mouse FSH) 48T/96T 進(jìn)口分裝

CLIAKitfom-1(MouseKidneyinjurymolecule1)ELISAKIT小鼠腎損傷分子1規(guī)格：48T/96T

通用型蛋白電泳考馬斯亮藍(lán)染色試劑盒10次

ELISAKitTGF-α大鼠轉(zhuǎn)化生長(zhǎng)因子α規(guī)格：48T/96T

磷酸化血小板源性生長(zhǎng)因子受體α費(fèi)用 大鼠蛋白激酶Cα相互作用蛋白1(PICK1)ELISA試劑盒 ，英文名： PICK1 ELISA Kit

Human P53 (P53) ELISA Kit 人P53(P53)ELISA試劑盒

Ratconnectivetissuegrowthfactor,CTGFELISAKit 大鼠結(jié)締組織生長(zhǎng)因子(CTGF)ELISA試劑盒 96T/48T 進(jìn)口分裝

CLIAKitforCXCL16(HumanCXC-chemokineligand16)ELISAKit人CXC趨化因子配體16規(guī)格：48T/96T

細(xì)胞砷元素比色法定量檢測(cè)試劑盒20次

RatFactorⅧ-relatedAigen,FⅧAgELISAKit大鼠第八因子相關(guān)抗原(FⅧAg)ELISA試劑盒規(guī)格：96T/48T